Pharmalot Ed Silverman STAT Plus: J&J agrees not to enforce patents on a key tuberculosis drug in dozens of poor countries
Pharmalot Ed Silverman STAT Plus: Generic makers fall short when providing access to low- and middle-income countries, analysis finds
Pharmalot Ed Silverman STAT Plus: Sales from controversial drug discount program rose to $54 billion last year
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals
Politics John Wilkerson STAT Plus: GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours
Pharmalot Ed Silverman STAT Plus: Drug industry payments to eye docs boosted Medicare spending on pricier treatments
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA advisers vote overwhelmingly against ALS treatment; weight-loss drugs scrutinized over reports of suicidal thoughts
Politics John Wilkerson STAT Plus: 6 ways the government could help address drug shortages, including in cancer
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pharma would lose loyal ally if Menendez leaves Senate; EMA to discuss anesthesia risk for weight-loss drugs
Politics Sarah Owermohle STAT Plus: With Menendez indictment, pharmaceutical industry could lose a key ally
D.C. Diagnosis Sarah Owermohle STAT Plus: Will a government shutdown stall Medicare drug price negotiations?
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA to furlough one-fifth of staff if government shuts down; FDA cites ‘grossly deficient’ data for ALS drug
Pharmalot Jonathan Wosen STAT Plus: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard
Pharmalot Ed Silverman STAT Plus: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny
Pharma Annalisa Merelli STAT Plus: Approval setback for EpiPen alternative puts spotlight on common anti-competition tactic
Pharmalot Ed Silverman STAT Plus: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback
Pharmalot Ed Silverman STAT Plus: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro
Pharmalot Ed Silverman STAT Plus: How a cash-prize system that phases out patents may lower drug prices
Politics John Wilkerson STAT Plus: PBMs were the target of House hearing, but pharma wasn’t spared criticism
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses
Pharmalot Ed Silverman STAT Plus: After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost
Pharmalot Ed Silverman STAT Plus: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing